ArticleLeukemia & lymphoma2020

How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?

R Andrew Harkins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.